Logo Image
|Articles|August 30, 2022

Life Sciences companies face difficulties incorporating ESG into their compliance programs

Hogan Lovells released a survey that tracked the thinking of compliance professionals who are implementing ESG into compliance programs.

ESG (environmental, social and governance) has become a top compliance concern for life sciences companies around the world—yet the evidence suggests that many are struggling to embed ESG into their existing compliance programs.

A survey of compliance professionals at 100 multinational life sciences companies globally reveals an overwhelming majority—84%—report that ESG risk is increasing as a priority for their board. Yet more than four in five also report that the failure to embed ESG into existing risk practices is impeding their organization’s ESG risk management.

Hogan Lovells’ Navigating Deep Waters survey, released today, tracks the thinking of experienced compliance professionals who are integrating the social and governance aspects of ESG into existing compliance programs.

Read more about Hogan Lovell's survey here.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more